Federal Circuit Won’t Rehear Obviousness-Type Double Patenting Case
WASHINGTON, D.C. — The Federal Circuit U.S. Court of Appeals on Sept. 10 denied generic drugmakers’ petition for panel rehearing or rehearing en banc, leaving in place a panel’s June opinion...To view the full article, register now.
Already a subscriber? Click here to view full article